Bristol Myers Squibb presented Phase 3 results for mezigdomide in the SUCCESSOR-2 study in relapsed or refractory multiple myeloma. In the trial, adding mezigdomide to carfilzomib and dexamethasone (MeziKd) delayed disease progression or death by about 10 months versus standard comparator therapy. BMS reported a 52% reduction in the risk of progression or death versus carfilzomib plus dexamethasone alone, and said the regimen delivered stronger disease control metrics, including higher response rates and a higher proportion of patients with no detectable trace of disease. Severe adverse events were more frequent in the mezigdomide arm. With Revlimid and Pomalyst facing long-standing competitive pressure, mezigdomide is one of BMS’s major next-generation options and is being tested as a successor in a rapidly evolving myeloma landscape.